SLC5A2 and metabolic dysfunction-associated steatohepatitis: These studies show that SGLT2 inhibitors not only help control blood sugar but also improve liver function, reduce fat mass, and lower liver inflammation, which contributes to a reduced risk of MASH progression and other complications associated with T2DM and MASLD.